Cytorreductive surgery and hyperthermic intraoperative chemotherapy for peritoneal carcinomatosis

Manejo de carcinomatosis peritoneal con citorreducción más quimioterapia hipertérmica intraoperatoria (HIPEC)

Introduction: cytorreductive surgery (CRS) paired with hyperthermic intraoperative chemotherapy (HIPEC), approach peritoneal carcinomatosis (PC) as a localized regional disease with adequate survival response according to disease severity. CRS with HIPEC is regarded as a highly morbid procedure with high mortality rates. Objective: to review the 1-year overall survival and disease-free survival in patients with PC that had been treated with CRS with HIPEC at Hospital Infantil Universitario de San José between January 2016 and December 2017. Methodology: an observational study analyzing a cohort of patients with PC secondary to various primary tumors who received CRS with HIPEC. Data was collected from clinical records. Results: we included 10 cases with mean age of 49 years (IQR 43-54) and PC secondary to appendix (60%, n=6), colon (20%, n=2) and ovary (20%, n=2) primary tumors. The peritoneal carcinomatosis index (PCI) was 14.5 (IQR 6-24). PC recurred in 3 patients and 4 patients died. A 1-year overall survival rate of 54% was estimated and a 1-year disease-free survival of 58% was obtained. Conclusion: our results of 1-year overall and disease-free survival rates were better to those described for systemic chemotherapy. Strict patient selection, as well as, conducting larger studies is recommended to allow an evidence-based determination of overall and disease-free survival in patients treated with CRS with HIPEC.

1. Chu DZJ, Lang NP, Thompson C, Osteen PK WK. Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7. doi: 10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v
2. Dawson LE, Russell AH TD. Adenocarcinoma of the Sigmoid Colon : Sites of Initial Dissemination and Clinical Patterns of Recurrence Following Surgery Alone. J Surg Oncol. 1983;99:95–9. doi: 10.1002/jso.2930220208
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M BP. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2015;3:581–92. doi: 10.1093/annonc/mdl498
4. Smith LE, Brodsky JT CA. Peritoneal Seeding Following Potentially Curative Resection of Colonic Carcinoma : Implications for Adjuvant Therapy. Dis Colon Rectum. 1991;34(8):723–7. doi: 10.1007/bf02050360
5. Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, George E et al. Adenocarcinoma of the retroperitoneal ascending and descending colon : sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys. 19839;3(361–365). doi: 10.1016/0360-3016(83)90297-3
6. Targarona EM, Martínez J, Nadal A, Balagué C, Cardesa A, Pascual S et al. Cancer Dissemination during Laparoscopic Surgery: Tubes, Gas, and Cells. World J Surg. 1998;22(1):55–61. doi: 10.1007/s002689900349
7. Jacquet P, Jelinek JS, Steves MA SP. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6. doi: 10.1002/1097-0142(19930901)72:5<1631::aid-cncr2820720523>3.0.co;2-i
8. Frederick. T. Lectures on the Anatomy of the Intestinal Canal and Peritoneum in Man. Br Med J. 1885;1(1262):470–4. doi: 10.1136/bmj.1.1262.470
9. González Barón M BM. Tratado de medicina paliativa y tratamiento de soporte del paciente con cáncer. Ed. Médica Panamericana. 2007.
10. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–6. doi: 10.1002/jso.20676
11. Esquivel J SP. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg. 2000;87(10):1414–8. doi: 10.1046/j.1365-2168.2000.01553.x
12. Price B. Analysis of Current Trends in United States Mesothelioma Incidence. Am J Epidemiol. 1997;145(3):211–8. doi: 10.1093/oxfordjournals.aje.a009093
13. Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW, Pisters PWT, Patel S et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94(9):2441–6. doi: 10.1002/cncr.10504
14. Tong D, Russell AH, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE et al. Adenocarcinoma of the cecum: natural history and clinical patterns of recurrence following radical surgery. Int J Radiat Oncol Biol Phys. 1983;9(3):357–60. doi: 10.1016/0360-3016(83)90296-1
15. Barrios P, Ramos I, Escayola C MM. Implementacion y desarrollo de un programa de tratamiento de la carcinomatosis peritoneal en Cataluna. Indicaciones y resultados clinicos con la tecnica de Sugarbaker. Catalan Agency Heal Information, Assess Qual (CAHIAQ -formerly CAHTA). 2009;
16. Sugarbaker PH, Stuart OA CC. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57(5):703–8. doi: 10.1007/s00280-005-0074-8
17. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin c after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138(1):26-33. doi: 10.1001/archsurg.138.1.26
18. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130–8. doi: 10.1159/000011847
19. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(22):256–60.
20. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cáncer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cáncer cell lines. Eur J Cancer. 1998;34(1):148–54. doi: 10.1016/s0959-8049(97)00370-5
21. Zhang L, Shen M, Zhang F, Tang F. Survival analysis and risk factors for mortality in connective tissue disease-associated pneumomediastinum. Rheumatol Int. 2014;34(12):1657–63. doi: 10.1007/s00296-014-3046-7
22. (ASCGO) AC de GO. Guía de práctica clínica. Manejo quirúrgico del cáncer epitelial de ovario. Asociación Colombiana de Ginecólogos Oncólogos (ASCGO), editor. Rev Colomb Obs Ginecol. 2016;67(2):120. dói: 10.18597/rcog.385.
23. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 2007;134:247–64. doi: 10.1007/978-0-387-48993-3_15
24. S. B. Peritoneum and Sepsis: The Role of Sepsis in the Genesis of Peritoneal Adhesions. In: K, Treutner S V., editor. Peritoneal Adhesions. Springer; 1997. p. 201–7.
25. Butterworth SA, Panton ON, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei. Am J Surg. 2002;183(5):529–32. doi: 10.1016/s0002-9610(02)00843-7
26. Editors T. Journal of Peritoneum (and other serosal surfaces). In: 10th International Congress on Peritoneal Surface Malignancies. 2016.
27. Sugarbaker PH. Metastatic inefficiency: The scientific basis for resection of liver metastases from colorectal cáncer. J Surg Oncol. 1993;53(S3):158–60.
28. Huhmann MB, Cunningham RS. Importance of nutritional screening in treatment of cancer-related weight loss. Lancet Oncol. 2005;6(5):334–43. doi: 10.1016/S1470-2045(05)70170-4
29. Verwaal VJ, Van Ruth S, De Bree E, van Sloothen GW, van Tinteren H, Boot H et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cáncer. J Clin Oncol. 2003;21(20):3737–43. doi: 10.1200/JCO.2003.04.187
30. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. doi: 10.1200/JCO.2008.19.7160
31. López-Basave HN, Morales-Vasquez F, Ruiz Molina JM et al. Citorreducción e HIPEC en carcinomatosis peritoneal. Experiencia del Instituto Nacional de Cancerología de México. Inst Nac Cancerol México. 2014;36(3):138-144.
32. Franko J, Ibrahim Z, Gusani NJ et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62. doi: 10.1002/cncr.25116